Published mark
Keros Therapeutics, Inc.
NASDAQ: KROS. Canonical company identity and public leadership record.
US
Record source reportedRecord not claimedNo Eval published
- Alpha ID
- alpha:company:bd231403-cb57-4a0b-a8d4-fc9dda4b42a1
- SEC CIK
- 0001664710
- Record version
- vpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce, published Oct 20, 2026
- Newest evidence
- Apr 22, 2026
- Monitoring
- Not yet monitored Details
- Integrity
- Not yet signed Methodology
- CEO
- Jasbir SeehraPresident and Chief Executive Officer
- Chair
- Jean-Jacques Bienaimé
- Independent
- Not published6 directors published
- Published claims
- 382 distinct sources
- Evidence records
- 40 pinned
- Source conflicts
- 0None open
Built from 2 distinct sources and 4 evidence records. Every Claim links to where it appears. Where nothing was published, the record states the coverage gap.
CorroboratedSource reportedAlpha inferenceNot disclosed
Public record. Alpha publishes governance facts about this organization from regulatory filings and company statements. Private enterprise overlay data is never projected here. The company can claim the record, correct, or dispute any Claim. How this works
DIRECTOR APPOINTED
Ran Nussbaum seat on Keros Therapeutics, Inc., effective 2026-04-22.
EffectiveEffective Apr 22, 2026E3
Monitoring
ContinuousWhat the published record states about identity, evidence, evaluation, monitoring, authority, and freshness. Watched-source schedules are not published for this record.
- IdentityunclaimedPublished
- Evidencesource_reportedPublished
- Evaluationnot_evaluatedPublished
- MonitoringNot yet published for this record.Not published
- AuthorityNot yet published for this record.Not published
- FreshnesscurrentPublished
Leadership
Evidence| Role | Person | Since | Status | Claim |
|---|---|---|---|---|
| Chief Legal Officer and Secretary | Esther Cho | Not captured | unknown | Source reportedE2 |
| President and Chief Executive Officer | Jasbir Seehra | Not captured | unknown | Source reportedE2 |
| Chief Financial Officer | Keith Regnante | Not captured | unknown | Source reportedE2 |
| Chief Scientific Officer | Lorena Lerner | Not captured | unknown | Source reportedE2 |
Board of directors
Evidence6 directors published. Independence determinations are not published for every director.
| Director | Status | Since | Committees | Claim |
|---|---|---|---|---|
| Alpna Seth | Independence not published | 2023 | Audit CommitteeCompensation CommitteeNominating and Corporate Governance Committee | Source reportedE3 |
| Julius Knowles | Independence not published | 2016 | Audit CommitteeCompensation CommitteeNominating and Corporate Governance Committee | Source reportedE3 |
| Mary Ann Gray | Independence not published | 2020 | Audit CommitteeCompensation CommitteeNominating and Corporate Governance Committee | Source reportedE3 |
| Nima Farzan | Independence not published | 2020 | Audit CommitteeCompensation CommitteeNominating and Corporate Governance Committee | Source reportedE3 |
| Ran Nussbaum | Independence not published | 2026 | Audit CommitteeCompensation CommitteeNominating and Corporate Governance Committee | Source reportedE3 |
| Tomer Kariv | Independence not published | 2026 | Audit CommitteeCompensation CommitteeNominating and Corporate Governance Committee | Source reportedE3 |
| Charles Newton | Independent | Not published | None published | Source reportedE2 |
| Jasbir Seehra | Not independent | Not published | Chief Executive Officer and Director | Source reportedE2 |
| Jean-Jacques Bienaimé | IndependentChair | Not published | None published | Source reportedE2 |
Committees and risk ownership
Evidence| Committee | Chair | Members | Risks assigned |
|---|---|---|---|
| Audit Committee | Not published | Alpna Seth, Julius Knowles, Mary Ann Gray, Nima Farzan, Ran Nussbaum, Tomer Kariv | Not described in the published record |
| Chief Executive Officer and Director | Not published | Jasbir Seehra | Not described in the published record |
| Compensation Committee | Not published | Alpna Seth, Julius Knowles, Mary Ann Gray, Nima Farzan, Ran Nussbaum, Tomer Kariv | Not described in the published record |
| Nominating and Corporate Governance Committee | Not published | Alpna Seth, Julius Knowles, Mary Ann Gray, Nima Farzan, Ran Nussbaum, Tomer Kariv | Not described in the published record |
Committee RecordAudit Committee: Chair not stated; Members Alpna Seth; Julius Knowles; Mary Ann Gray; Nima Farzan; Ran Nussbaum; Tomer Kariv
Committee AppointmentAlpna Seth: member, Audit Committee
Committee AppointmentJulius Knowles: member, Audit Committee
Committee AppointmentMary Ann Gray: member, Audit Committee
Committee AppointmentNima Farzan: member, Audit Committee
Committee AppointmentRan Nussbaum: member, Audit Committee
Committee AppointmentTomer Kariv: member, Audit Committee
Committee RecordCompensation Committee: Chair not stated; Members Alpna Seth; Julius Knowles; Mary Ann Gray; Nima Farzan; Ran Nussbaum; Tomer Kariv
Committee AppointmentAlpna Seth: member, Compensation Committee
Committee AppointmentJulius Knowles: member, Compensation Committee
Committee AppointmentMary Ann Gray: member, Compensation Committee
Committee AppointmentNima Farzan: member, Compensation Committee
Committee AppointmentRan Nussbaum: member, Compensation Committee
Committee AppointmentTomer Kariv: member, Compensation Committee
Committee RecordNominating and Corporate Governance Committee: Chair not stated; Members Alpna Seth; Julius Knowles; Mary Ann Gray; Nima Farzan; Ran Nussbaum; Tomer Kariv
Committee AppointmentAlpna Seth: member, Nominating and Corporate Governance Committee
Committee AppointmentJulius Knowles: member, Nominating and Corporate Governance Committee
Committee AppointmentMary Ann Gray: member, Nominating and Corporate Governance Committee
Committee AppointmentNima Farzan: member, Nominating and Corporate Governance Committee
Committee AppointmentRan Nussbaum: member, Nominating and Corporate Governance Committee
Committee AppointmentTomer Kariv: member, Nominating and Corporate Governance Committee
Control and voting power
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Authority to act
Evidence and agent registryWho can act for the company, and on whose authority. This is what a counterparty's agent checks before it accepts an order, signs, or pays.
Principal executive officerJasbir Seehra, President and Chief Executive Officer
Who can authorize an agentNot assessedNo Alpha inference about signing authority or board-reserved matters is published for this record.
Not assessed
AI agents registered by the companyNot registered in the public RegistryAgent Deployments, Agent Use Cases, Authority Grants, TrustChecks, Action Ledger entries and Governance Receipts live in the private enterprise overlay. They are never projected into the public Registry without explicit cross-plane authorization. Absence here is a plane boundary, not evidence that the enterprise operates no agents.
Agent registry
Delegations publishedNot disclosedBoard and officer delegation resolutions are not public filings and are not published in this record.
Search scope
Financials and market context
EvidenceSecurity ListingKROS (NASDAQ)
Index membershipsNo current membership is published in Alpha's tracked index universe.This is not evidence that the company is absent from every market index.
None publishedAs of Oct 20, 2026. Rights-filtered public evidence only; no redistribution or model training is granted. Only source-backed memberships with an explicit public redistribution basis are returned.
Governance and policies
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Risk, audit, and cyber
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
AI oversight and accountability
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Legal and regulatory
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Compensation
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Other published claims
EvidencePublished Claims that belong to no section above. Each keeps its permalink, evidence, and assertion state.
Legal NameKeros Therapeutics, Inc.
Entity StatusPublic listing published
Published FactUS
Not yet in this record
CoverageA gap is a coverage state, not a negative finding. These sections are expected for this entity class and are not yet published.
- Corporate structureNot reviewed. Parent, subsidiary and predecessor structure explains who is governed.
- OwnershipNot reviewed. Ownership and voting power determine who can influence the board.
- FinancialsNot reviewed. Governance-relevant financial context frames capital and audit decisions.
- CompensationNot reviewed. Pay design shows how incentives are governed.
- GovernanceNot reviewed. Governing documents and provisions set the rules of the enterprise.
- Shareholder governanceNot reviewed. Meeting and vote records show shareholder dissent and support.
- AuditNot reviewed. Auditor, controls and restatements show assurance over reporting.
- LegalNot reviewed. Material legal and regulatory matters show enforcement exposure.
- RiskNot reviewed. Risk ownership links the board, committees, executives and controls.
- CyberNot reviewed. Cyber and data governance is a disclosed oversight domain.
- AI governanceNot reviewed. AI oversight is a differentiated Alpha governance domain.
- Markets externalNot reviewed. Auditors, advisors, investors and regulators form the external ecosystem.
- Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.
- Only explicitly published canonical company identity and current confirmed public roles are included.Only explicitly published canonical company identity and current confirmed public roles are included.
- Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.
- Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.
- This Company Profile is an identity and evidence record, not an Alpha rating.This Company Profile is an identity and evidence record, not an Alpha rating.
Linked people
Same claims as person records- Esther ChoChief Legal Officer and Secretarycompany:bd231403-cb57-4a0b-a8d4-fc9dda4b42a1:leadership_role:14
- Jasbir SeehraPresident and Chief Executive Officer; President, Chief Executive Officer and Directorcompany:bd231403-cb57-4a0b-a8d4-fc9dda4b42a1:leadership_role:15, company:bd231403-cb57-4a0b-a8d4-fc9dda4b42a1:leadership_role:8
- Keith RegnanteChief Financial Officercompany:bd231403-cb57-4a0b-a8d4-fc9dda4b42a1:leadership_role:16
- Lorena LernerChief Scientific Officercompany:bd231403-cb57-4a0b-a8d4-fc9dda4b42a1:leadership_role:17
- Alpna SethDirectorcompany:bd231403-cb57-4a0b-a8d4-fc9dda4b42a1:leadership_role:6
- Julius KnowlesDirectorcompany:bd231403-cb57-4a0b-a8d4-fc9dda4b42a1:leadership_role:9
- Mary Ann GrayDirectorcompany:bd231403-cb57-4a0b-a8d4-fc9dda4b42a1:leadership_role:10
- Nima FarzanDirectorcompany:bd231403-cb57-4a0b-a8d4-fc9dda4b42a1:leadership_role:11
- Ran NussbaumDirectorcompany:bd231403-cb57-4a0b-a8d4-fc9dda4b42a1:leadership_role:12
- Tomer KarivDirectorcompany:bd231403-cb57-4a0b-a8d4-fc9dda4b42a1:leadership_role:13
- Charles NewtonDirectorcompany:bd231403-cb57-4a0b-a8d4-fc9dda4b42a1:leadership_role:7
- Jean-Jacques BienaiméChair of the Boardcompany:bd231403-cb57-4a0b-a8d4-fc9dda4b42a1:leadership_role:5
Subject and corrections
Public-role doctrineThis record exists because the company is in the published Registry. The company can claim the record, correct, or dispute any Claim. Corrections are versioned and the original stays in history.
- Basis
- Published company record built from public sources
- Sources
- 4 evidence records cited. 0 with redistribution rights.
- Never published
- Private enterprise overlay data: deployments, authority grants, TrustChecks, receipts, telemetry
- Record claimed
- No
- Open disputes
- 0
- Identity ownership
- unclaimed
Claiming not yet available
If the company claims the record, its statements appear as their own assertion state and never overwrite the cited evidence.
Evidence
Authority and rights- E1Alpha canonical company public projection. canonical identity. Retrieved Oct 20, 2026. Cited by 4 Claims.
- E2sec def 14a. Published Apr 22, 2026. Retrieved Sep 6, 2026. Cited by 7 Claims.
- E3sec proxy. Published Apr 22, 2026. Retrieved Sep 2, 2026. Cited by 6 Claims.
- E4governance_people_committees. sec proxy. Cited by 21 Claims.
What changed in version public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce
vpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce published Oct 20, 2026- Ran Nussbaum seat on Keros Therapeutics, Inc., effective 2026-04-22.
- Tomer Kariv seat on Keros Therapeutics, Inc., effective 2026-04-22.
- Alpna Seth seat on Keros Therapeutics, Inc., effective 2023-01-01.
- Mary Ann Gray seat on Keros Therapeutics, Inc., effective 2020-01-01.
- Nima Farzan seat on Keros Therapeutics, Inc., effective 2020-01-01.
- Julius Knowles seat on Keros Therapeutics, Inc., effective 2016-01-01.